Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566852 · ClinicalTrials.gov registry record · Phase 3
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 554
- Enrollment target
NCT00566852 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 554 participants.
The verdict
NCT00566852, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 554 participants
- Enrollment target
Study Summary
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy. PURPOSE: This randomized phase III trial is studying memantine to see how well it works compared to a placebo in preventing side effects caused by whole-brain radiation therapy in patients with brain metastases from solid tumors.
Interventions
- OTHER Placebo
- DRUG Memantine
- RADIATION Whole brain radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 554 participants |
| Start Date | 2008-03 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00566852
The ClinicalTrials.gov registry entry for NCT00566852 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 554 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00566852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00566852 about?
NCT00566852 is a clinical study titled "Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors". RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy. PURPOSE: This randomized phase III trial is studying memantine to see how well it work...
What is the current status of trial NCT00566852?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 554 participants. The study started on 2008-03. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00566852?
The interventions under investigation include: Placebo (OTHER), Memantine (DRUG), Whole brain radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00566852?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.